RESUMO
Development of anthrax countermeasures that may be used concomitantly in a postexposure setting requires an understanding of the interaction between these products. Anthrax immune globulin intravenous (AIGIV) is a candidate immunotherapeutic that contains neutralizing antibodies against protective antigen (PA), a component of anthrax toxins. We evaluated the interaction between AIGIV and BioThrax (anthrax vaccine adsorbed) in rabbits. While pharmacokinetics of AIGIV were not altered by vaccination, the vaccine-induced immune response was abrogated in AIGIV-treated animals.
Assuntos
Vacinas contra Antraz/administração & dosagem , Anticorpos Antibacterianos/administração & dosagem , Imunoglobulinas Intravenosas/farmacocinética , Animais , Antraz/imunologia , Antraz/microbiologia , Antraz/prevenção & controle , Vacinas contra Antraz/imunologia , Anticorpos Antibacterianos/sangue , Anticorpos Antibacterianos/imunologia , Área Sob a Curva , Bacillus anthracis/imunologia , Antagonismo de Drogas , Feminino , Meia-Vida , Humanos , Imunoglobulinas Intravenosas/sangue , Imunoglobulinas Intravenosas/imunologia , Infusões Intravenosas , Masculino , Coelhos , Infecções Respiratórias/imunologia , Infecções Respiratórias/microbiologia , Infecções Respiratórias/prevenção & controle , VacinaçãoRESUMO
Bacillus anthracis toxins can be neutralized by antibodies against protective antigen (PA), a component of anthrax toxins. Anthrivig (human anthrax immunoglobulin), also known as AIGIV, derived from plasma of humans immunized with BioThrax (anthrax vaccine adsorbed), is under development for the treatment of toxemia following exposure to anthrax spores. The pharmacokinetics (PK) of AIGIV was assessed in naive animals and healthy human volunteers, and the efficacy of AIGIV was assessed in animals exposed via inhalation to aerosolized B. anthracis spores. In the clinical study, safety, tolerability, and PK were evaluated in three dose cohorts (3.5, 7.1, and 14.2 mg/kg of body weight of anti-PA IgG) with 30 volunteers per cohort. The elimination half-life of AIGIV in rabbits, nonhuman primates (NHPs), and humans following intravenous infusion was estimated to be approximately 4, 12, and 24 days, respectively, and dose proportionality was observed. In a time-based treatment study, AIGIV protected 89 to 100% of animals when administered 12 h postexposure; however, a lower survival rate of 39% was observed when animals were treated 24 h postexposure, underscoring the need for early intervention. In a separate set of studies, animals were treated on an individual basis upon detection of a clinical sign or biomarker of disease, namely, a significant increase in body temperature (SIBT) in rabbits and presence of PA in the serum of NHPs. In these trigger-based intervention studies, AIGIV induced up to 75% survival in rabbits depending on the dose and severity of toxemia at the time of treatment. In NHPs, up to 33% survival was observed in AIGIV-treated animals. (The clinical study has been registered at ClinicalTrials.gov under registration no. NCT00845650.).
Assuntos
Vacinas contra Antraz/administração & dosagem , Antraz/prevenção & controle , Anticorpos Antibacterianos/administração & dosagem , Bacillus anthracis/efeitos dos fármacos , Imunoglobulinas Intravenosas/farmacocinética , Infecções Respiratórias/prevenção & controle , Esporos Bacterianos/efeitos dos fármacos , Animais , Antraz/imunologia , Antraz/microbiologia , Antraz/mortalidade , Vacinas contra Antraz/imunologia , Anticorpos Antibacterianos/imunologia , Anticorpos Antibacterianos/isolamento & purificação , Antígenos de Bactérias/sangue , Antígenos de Bactérias/imunologia , Bacillus anthracis/imunologia , Bacillus anthracis/patogenicidade , Toxinas Bacterianas/sangue , Toxinas Bacterianas/imunologia , Biomarcadores/análise , Método Duplo-Cego , Feminino , Meia-Vida , Humanos , Imunoglobulinas Intravenosas/imunologia , Imunoglobulinas Intravenosas/isolamento & purificação , Infusões Intravenosas , Macaca fascicularis , Masculino , Coelhos , Infecções Respiratórias/imunologia , Infecções Respiratórias/microbiologia , Infecções Respiratórias/mortalidade , Esporos Bacterianos/imunologia , Esporos Bacterianos/patogenicidade , Análise de Sobrevida , Fatores de Tempo , VacinaçãoRESUMO
A new oral polio vaccine, nOPV2, has become the first vaccine to pursue a WHO Emergency Use Listing. Many lessons were learned as part of the accelerated development plan and submission, which have been categorized under the following sections: regulatory, clinical development, chemistry manufacturing and controls, and post-deployment monitoring. Efforts were made to adapt findings from these studies to COVID-19 vaccine candidates. Specific concepts for accelerating COVID-19 vaccine development across multiple functional domains were also included. The goals of this effort were twofold: (1) to help familiarize vaccine developers with the EUL process; and (2) to provide general guidance for faster development and preparations for launch during the COVID-19 pandemic.